King was in charge when we dropped Oncolym Moby. Oncolym last mentioned in a 2004 filing. Phase III was approved under Legere's reign. King was in charge when we went from Cotara Phase III approval to Cotara Phase I. I always believed we should have continued the original Cotara Phase III and after getting marketing approval we could have went for the new delivery system. The results of the original Phase II were better than the SOC.
To the posters who say some want a fire sale of Peregrine's pipeline read the following from a filing.
In addition to equity financing, the Company is actively exploring various other sources of cash by leveraging its various assets. The transactions being explored by the Company for its technologies include licensing, partnering or the sale of Cotara(TM), Oncolym(R), or various portions of its VTA and VEA technologies that it does not plan on developing internally.
In over 5 years Kings hasn't accomlished any of this. These aren't my words, the thoughts of other investors. It's in the filings. Does not plan on developing internally means just what it says. It sits on the shelf dying a slow death as science marchs on!
News 
Market Data 
Discover 
AI
